DLL3-Targeted Antibody & Cell Therapy – Target Pipeline List 06/2019
Targets: Delta-like ligand 3; DLL3
This Target Pipeline List provides an overview of DLL3-targeted antibody and cell therapeutics in development for treatment of small cell lung cancer (SCLC).
SCLC is an aggressive neuroendocrine tumor; response to initial chemotherapy and radiotherapy is often followed by recurrence, rapid progression, and resistance to current therapies. Delta-like ligand 3 (DLL3) is an inhibitory ligand of Notch receptors that is expressed in most SCLC tumors but minimally expressed in normal tissues. DLL3 may therefore be a promising target for DLL-3 targeted enhanced antibody and cell therapies.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.